KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Current Assets

Last Annual Value

118.81M

3-Year CAGR

212%

5-Year CAGR

-20%

10-Year CAGR

-11%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Current Assets

KLRS · NASDAQ
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
118.81M
229.1%-14.1%N/A 
90.45M
-6.2%-13.8%5.6%
112.67M
12.2%-7.0%N/A
82.47M
-16.8%-22.1%N/A
68.35M
62.1%5.9%N/A
165.54M
-15.9%8.7%N/A
131.30M
8.5%-16.2%-5.3%
50.73M
-35.5%-32.7%N/A
87.58M
34.9%-1.9%N/A
52.11M
-20.1%-10.7%N/A
133.27M
-6.4%6.9%15.6%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7